Partnering

OxSonics^® has an active and diverse partnering programme and is open to exploring new and innovative collaboration partnerships.

An important feature of SonoTran is that it can be utilized in conjunction with therapeutic agents without any need for reformulation. Partnering opportunities exist for therapeutic agents in pre-clinical and clinical development as well as in-market agents.

If you would like to learn more about what SonoTran can do for your therapeutic agent, please contact us.

SonoTran is designed to…

Increase efficacy

By enhancing the dose and distribution throughout solid tumour tissues.

Reduce toxicity

By enhancing tumour dose whilst administering lower systemic dose.

Enable new delivery routes & indications

By overcoming PK-related limitations.

Salvage failed therapeutic agents

By enhancing efficacy at or below the maximum tolerated and/or maximum feasible dose.

Extend patent life

By combining an off-patent therapeutics agent with patent protected SonoTran technology.

Deliver value

By providing both clinicially enabling and commercially differentiating solutions.

SonoTran System Management

OxSonics plans to provide the installed base of SonoTran Systems alongside the provision of training and service and maintenance of Systems. This allows our strategic partners to focus on the commercialisation of the SonoTran Particles in combination with their therapeutic agent.